Microbot Medical Inc. (NASDAQ:MBOT) Short Interest Update

Microbot Medical Inc. (NASDAQ:MBOT) saw a large increase in short interest in February. As of February 13th, there was short interest totaling 7,358,340 shares, an increase of 21.8% from the January 29th total of 6,040,735 shares. Based on an average daily volume of 3,709,221 shares, the short-interest ratio is currently 2.0 days. Approximately 11.5% of the company’s stock are short sold. Approximately 11.5% of the company’s stock are short sold. Based on an average daily volume of 3,709,221 shares, the short-interest ratio is currently 2.0 days.

Microbot Medical Stock Performance

Microbot Medical stock opened at $2.39 on Wednesday. The firm’s 50-day moving average is $2.08 and its 200-day moving average is $2.55. Microbot Medical has a 1 year low of $1.25 and a 1 year high of $4.67. The company has a market cap of $160.51 million, a P/E ratio of -5.31 and a beta of 1.22.

Hedge Funds Weigh In On Microbot Medical

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Microbot Medical by 14.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock worth $7,148,000 after purchasing an additional 292,923 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in shares of Microbot Medical by 1.8% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,480,000 shares of the biotechnology company’s stock valued at $2,960,000 after acquiring an additional 26,000 shares during the period. CIBC Bancorp USA Inc. bought a new position in shares of Microbot Medical during the third quarter worth about $4,435,000. Heights Capital Management Inc. acquired a new stake in shares of Microbot Medical in the 3rd quarter worth about $2,693,000. Finally, Geode Capital Management LLC lifted its position in Microbot Medical by 54.4% in the 4th quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 268,609 shares during the last quarter. 16.30% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Roth Mkm started coverage on shares of Microbot Medical in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price target for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Microbot Medical in a research report on Friday, November 28th. Finally, B. Riley Financial assumed coverage on shares of Microbot Medical in a research note on Tuesday, February 10th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Microbot Medical has an average rating of “Moderate Buy” and a consensus price target of $7.50.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.